Lisinopril, Anesthesia, and Perioperative Interactions: What Patients and Clinicians Need to Know

Lisinopril is an oral ACE (angiotensin-converting enzyme) inhibitor used for hypertension, heart failure with reduced ejection fraction, and after certain heart attacks. It is sold generically and under older brand names such as Prinivil and Zestril. It is not the same drug as an ARB (angiotensin receptor blocker, e.g., losartan) or a direct renin inhibitor (aliskiren), though all three act on the renin-angiotensin-aldosterone system (RAAS) and raise similar perioperative questions.

The direct answer

Lisinopril removes a compensatory pathway (angiotensin II-driven vasoconstriction) that the body normally uses to counteract the vasodilation caused by general anesthetics and neuraxial blocks. This is an established, mechanism-based interaction, not a pharmacokinetic one, lisinopril does not meaningfully change how anesthetic drugs are metabolized. Because of this, patients who take an ACE inhibitor close to the time of anesthesia are more likely to develop intraoperative hypotension that responds poorly to phenylephrine or ephedrine and better to vasopressin-pathway agents. The clinical question is not whether this interaction exists, it is well established, but which patients gain more from temporarily holding a dose versus a full discontinuation protocol (most people treated for hypertension) versus which patients gain more from continuing it (patients with reduced ejection fraction or recent myocardial infarction, where abrupt withdrawal carries its own risk). That distinction, not a blanket hold-or-continue rule, is what current guidance is built around.

Why ACE inhibitors and anesthesia are a recognized combination to plan around

Lisinopril blocks the conversion of angiotensin I to angiotensin II, which lowers systemic vascular resistance. That mechanism treats hypertension effectively but also removes a compensatory response the body relies on during anesthesia. General anesthetics and neuraxial blocks (spinal, epidural) cause vasodilation on their own. Normally, a drop in blood pressure triggers a rise in angiotensin II that restores vascular tone. Lisinopril blunts that rise, so the patient's remaining defenses against hypotension are sympathetic catecholamines and vasopressin, both of which can also be dampened by opioids and other anesthetic agents.

Older prospective studies from the 1990s and a body of subsequent work have reported that patients who continue an ACE inhibitor through the morning of surgery experience intraoperative hypotension considerably more often than patients who hold the dose beforehand. The exact frequencies cited in different papers vary, and the specific percentages that circulate in secondary sources (including earlier versions of interaction summaries like this one) should be checked against the original trial publications before being quoted as fixed figures. What is consistent across the literature is the direction of effect: continuing right up to surgery increases hypotension risk relative to holding it.

Why standard vasopressors can underperform

Phenylephrine and ephedrine partly depend on an intact renin-angiotensin system to sustain their pressor effect. When that system is pharmacologically suppressed, these agents can be less reliable. Vasopressin acts on V1 receptors independently of angiotensin II, which is the physiologic reason it is often favored as a rescue agent for ACE-inhibitor-associated refractory hypotension. This is a plausible and widely taught mechanism, but the comparative trial evidence behind it (including specific agents like terlipressin) is smaller and older, and dosing decisions in this setting belong to the anesthesia team managing the case, not to a patient-facing guide.

What perioperative guidelines actually say

Both the American College of Cardiology/American Heart Association (ACC/AHA) 2014 perioperative guideline and the European Society of Cardiology/European Society of Anaesthesiology (ESC/ESA) 2022 update address ACE inhibitors, and their language is more permissive than a firm mandate in either direction. The ACC/AHA guideline has historically described continuation of ACE inhibitors as "reasonable," while allowing that holding the dose and restarting postoperatively is also reasonable. The more recent European guidance leans toward suggesting a preoperative hold in patients whose hypertension is otherwise well controlled. Because guideline documents are periodically revised, the exact wording, evidence grade, and any changes to these recommendations since 2022 should be confirmed against the current published guideline text rather than relied on secondhand.

A large randomized trial (STOP-or-NOT, published in The Lancet in 2021) compared continuing versus holding renin-angiotensin-system inhibitors, including ACE inhibitors, before major non-cardiac surgery and found more intraoperative hypotension in the continuation group, without a clear difference in 30-day mortality or major cardiovascular events in that trial. This is genuine trial-level evidence for the hemodynamic outcome; the mortality finding should be read as reassuring but not as proof of equivalence, since the trial was not necessarily powered to detect small mortality differences. The precise event rates reported in that trial are the kind of number that deserves a direct check against the published paper rather than an inherited citation, and are not restated here as fixed figures.

In practical terms: for a patient taking lisinopril for hypertension alone, with good blood pressure control, most anesthesia teams will hold the morning dose before general anesthesia and restart once the patient is eating, drinking, and hemodynamically stable, typically within one to two days after surgery. This reflects a mechanism that is well established (loss of RAAS compensation under anesthesia) combined with guideline language that gives clinicians latitude rather than a single fixed rule, so the specific plan for any individual patient is a clinical judgment made by the surgical and anesthesia team, not a decision to make unilaterally at home.

What is established, what is plausible, and what is not established

Before applying any of this to an individual patient, it helps to separate the confidence levels behind different pieces of the lisinopril-anesthesia story.

Evidence-status assessment: lisinopril and perioperative/anesthesia interactions

Practical approach by patient type

No single rule fits every patient. The decision to hold or continue lisinopril depends on why the drug was prescribed, the type of anesthesia planned, and the patient's baseline kidney function and blood pressure control.

Patients most likely to have the dose held

• Hypertension as the only indication, with stable, well-controlled blood pressure
• General anesthesia or neuraxial (spinal/epidural) anesthesia planned
• Concurrent loop diuretic use, which compounds volume depletion
• Reduced kidney function (this should be assessed by the clinical team, not self-estimated)
• Procedures with anticipated significant blood loss

Patients where continuation is more often considered

• Heart failure with reduced ejection fraction, where abrupt ACE-inhibitor withdrawal can worsen hemodynamics
• Recent myocardial infarction
• Uncontrolled hypertension where stopping the drug creates its own acute risk

In these situations, the decision is individualized, ideally with direct communication between the prescribing cardiologist and the anesthesia team, and with vasopressin or a similar agent available at induction if continuation is chosen.

Restarting after surgery

Postoperative patients are often volume-depleted from fasting, fluid shifts, and blood loss. Restarting an ACE inhibitor too early in that state adds acute kidney injury risk on top of the surgical stress itself. Most clinicians wait until the patient is tolerating oral intake and appears hemodynamically stable before restarting, which in practice is often one to two days after surgery, but this timing is a clinical decision made by the treating team based on the individual patient's fluid status and kidney function, not a fixed rule to self-apply.

Lisinopril and alcohol: a separate, pharmacodynamic interaction

Alcohol causes vasodilation through several mechanisms, including nitric oxide release and direct smooth-muscle relaxation. Combined with lisinopril's own vasodilatory effect, alcohol can produce additive blood-pressure lowering, dizziness, or fainting. This is a pharmacodynamic interaction (two drugs pushing blood pressure in the same direction), not a pharmacokinetic one (alcohol does not meaningfully change how lisinopril is metabolized).

No large randomized trial isolating the lisinopril-alcohol combination specifically was identified in the material behind this article, so any precise numeric risk figure for this pairing should be treated as unverified rather than repeated as fact. What can be said with more confidence, based on general ACE-inhibitor prescribing precautions, is that conditions causing volume depletion or additional vasodilation, dehydration, heat, diarrhea, vomiting, or alcohol, raise the risk of an excessive blood pressure drop in patients on this class of drug. Prescribing information for ACE inhibitors as a class commonly warns about this general category of risk; the specific current label language should be checked at the FDA's Drugs@FDA database rather than assumed from a secondary summary, since label text is updated periodically.

Practical guidance that follows from the general pharmacology, without a dedicated interaction trial to cite:

• A single standard drink in a well-hydrated person with stable blood pressure is unlikely to cause serious harm, but this is a general inference, not a tested threshold specific to lisinopril
• Risk plausibly rises with more than one or two drinks per occasion, drinking on an empty stomach, hot weather, concurrent diuretic use, and age over 65
• People who feel dizzy after drinking while on lisinopril should sit or lie down, avoid driving, and avoid hot tubs or saunas, which add further vasodilation

Other perioperative interactions worth knowing about

NSAIDs, including ketorolac

NSAIDs inhibit prostaglandin synthesis, which blunts the renal vasodilatory response that ACE-inhibitor-treated kidneys depend on to maintain filtration when blood volume is low. The combination is associated with a meaningfully higher risk of acute kidney injury than either drug alone in observational data, though the precise odds-ratio figure attached to this claim in earlier versions of this article should be verified against the original case-control study before being used clinically. If postoperative pain control requires an NSAID in a patient on lisinopril, kidney function should be monitored.

Potassium handling: diuretics, potassium supplements, and succinylcholine

ACE inhibitors reduce aldosterone, which raises serum potassium. Perioperative potassium supplementation, or use of succinylcholine for intubation (which causes its own transient potassium rise), can push a lisinopril-treated patient toward clinically significant hyperkalemia, particularly with reduced kidney function. Baseline potassium should be checked before either supplementation or a succinylcholine-based induction plan in these patients.

Special situation: cardiac surgery

Cardiac surgery on cardiopulmonary bypass is mechanistically different from non-cardiac surgery, because bypass maintains perfusion pressure mechanically during the period when hypotension would otherwise be uncorrected. Some observational and trial data suggest continuing ACE inhibitors through cardiac surgery does not necessarily increase vasopressor requirements the way it does in non-cardiac, non-bypass settings, but this literature is smaller and institutional protocols vary considerably. This is a case where the operating cardiac surgical and anesthesia team's own protocol should take precedence over general guidance written for non-cardiac surgery.

What patients should tell their surgical team

• The exact lisinopril dose and time of the last dose taken
• Whether they also take a diuretic, an ARB, or a direct renin inhibitor (aliskiren)
• Recent blood pressure readings and whether control has been stable
• Any history of dizziness on standing, prior anesthesia complications, or kidney disease

Patients should not stop lisinopril on their own without instruction from the prescribing clinician or the surgical team. Abrupt discontinuation in someone with poorly controlled hypertension can cause rebound blood pressure elevation, and the hold-versus-continue decision depends on details (indication, kidney function, surgery type) that are best worked through with the clinical team rather than decided at home from a general guide.

When to seek urgent care

Anyone who develops severe dizziness, fainting, chest pain, confusion, or a sudden drop in urine output in the days after surgery while on or recently restarted on lisinopril should be evaluated urgently rather than waiting for a scheduled follow-up. These can be signs of significant hypotension, kidney injury, or another perioperative complication that needs prompt assessment.